RCRita Christopher

Rita Christopher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rita Christopher has a total of 177 co-authors. Here are the top co-authors by number of shared publications:

  • Sadanandavalli Retnaswami Chandra

    National Institute of Mental Health and Neuro Sciences

    12 shared publications
  • Manjunath Supriya

    Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences, Bengaluru 560029, India

    11 shared publications
  • Dindagur Nagaraja

    Department of Neurology, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India

    10 shared publications
  • Bhagavatula Indira Devi

    Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India

    7 shared publications
  • Puttachandra Prabhakar

    Department of Neurochemistry, National Institute of Mental Health and Neuro Sciences, Bengaluru 560029, India

    7 shared publications
  • Dhananjaya Ishwar Bhat

    Department of Neurosurgery, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India

    6 shared publications

Latest Publications

  • Open Access

    Clinical outcome in ischemic stroke patients on low dose enteric coated aspirin with serially evaluated platelet aggregation profile using light transmission aggregometry

    by Srijithesh Pr, Kr Ramya, Mythirayee Sivasubramanian, P Sundaravadivel, Priyamvada Sharma, Ravi Yadav, Rita Christopher

    Background:,Enteric-coated aspirin (ECA) is widely prescribed for secondary stroke prevention. The bioavailability and antiplatelet efficacy of enteric coated aspirin may be suboptimal. This study aimed to evaluate aspirin responsiveness in ischemic stroke patients using light transmission aggregometry (LTA) and serum thromboxane-B2 levels and clinical outcome in a longitudinal follow-up.,Methods:,In this prospective cohort study, ischemic stroke patients on 75-150 mg/day ECA were assessed using LTA with arachidonic acid (AA) and adenosine diphosphate (ADP) as agonists. Patients were categorized as responders, non-responders, or semi-responders based on inhibition platelet aggregation of both, either or none of the agonists used Serum thromboxane B2 levels and plasma salicylic acid concentrations were measured to assess response and compliance. The studies were repeated on follow-up to evaluate temporal concordance. Clinical outcome in the form of vascular events or death was assessed in the follow-up at 3 months, 6 months, 18 months and 24 months.,Results:,Aspirin non-responsiveness was observed in 8.6%, and semi-responsiveness in 34.5%. Serum thromboxane B2 levels were significantly higher in non-responders (median 5.03 ng/ml) than in responders (1.23 ng/ml, p<0.001). AA-semi-responders exhibited thromboxane profiles similar to non-responders. Among patients with assured compliance, 11.8% exhibited inadequate thromboxane suppression. Aspirin non-responders and AA-semi-responders had a higher rate of vascular events and a hazard ratio of 5.5 for adverse outcomes.,Conclusions:,A significant proportion of ischemic stroke patients on enteric-coated aspirin demonstrate incomplete platelet inhibition. Monitoring aspirin responsiveness through LTA and thromboxane levels may help identify patients at risk and guide individualized antiplatelet strategies.

  • Low plasma vitamin B6 levels are independently associated with ischemic stroke risk in young south Indian adults: A case-control study

    by Kondapura Jayadevappa Rudreshkumar, Sundaravadivel Pandarisamy, Dindagur Nagaraja, Rita Christopher

  • Open Access

    Influence of Estradiol and Estrogen Receptors on NOS3 Expression and Nitric Oxide Release: Implications for Intracranial Aneurysm Formation and Rupture

    by Shruthi Shimoga Ramesh, Rita Christopher, Bhagavatula Indira Devi, Dhananjaya Ishwar Bhat, Dhaval Shukla

    The prevalence of intracranial aneurysms (IAs) and aneurysmal subarachnoid hemorrhage (aSAH) due to IA rupture, is higher in postmenopausal compared with premenopausal women and men in the same age group. This is presumably due to reduced levels of the vascular protective hormone, estradiol. Experimental studies have revealed direct effects of estradiol on the vascular endothelium. Our aim was to determine the influence of estradiol and estrogen receptors on cerebral vasculature and the role of estrogen-mediated nitric oxide (NO) pathway in the formation and rupture of IAs. We measured circulatory estradiol and NO levels and the relative expression of genes involved in estrogen-mediated NO synthesis in 349 aSAH patients and 360 age- and gender-matched controls. We observed significantly reduced serum estradiol and NO levels in aSAH patients compared with controls. The expression of endothelial NO synthase gene (NOS3), estrogen receptor genes (ESR1, ESR2), and the kinases (SRC, AKT1, PIK3R1) involved in NO synthesis was significantly reduced in IA tissues compared with controls. Serum estradiol positively and significantly correlated with NO levels. Our results indicate that the activity of endothelial NO synthase and the bioavailability of NO may be regulated by estradiol and estrogen receptors to maintain cerebral vascular tone.

  • The AgeWell Index: An RF-Seeded Adaptive Genetic Algorithm for Explainable Aging Assessment in Mid-Life Adults

    by Preksha Kamalesh Babu, Navyashree S P, Sudeepa Roy Dey, Deepa Suryaprasad, Rita Christopher, Sundaravadivel P

    Successful aging encompasses a complex interplay of physical, mental, and functional health, yet existing clinical practice lacks a unified metric for care in mid-life adults. We introduce the AgeWell Index, a composite, data-driven scoring system that synthesizes four key domains-physical health, ac-tivities of daily living (ADL), mobility, and mental health-into a single, interpretable measure for the Indian mid-life population. Our approach utilizes a novel two-stage weighting architecture, where initial weights from a Random Forest seed a Genetic Algorithm to engineer a robust, additive index. This methodology is validated through a four-layer process, ensuring stability across algorithms, cohorts, and analytical frameworks. We assessed internal consistency with Cronbach's alpha (a = 0.63) and integrated SHAP analyses to provide transparent, individual-level insights. The AgeWell Index reliably stratifies aging profiles and, critically, uncovers a profound gender disparity, revealing that middle-aged men are more than twice as likely to be “Successful Agers” as women. This framework offers clinicians and policy-makers a robust tool to monitor health status, guide targeted interventions, and address the silent health crisis confronting middle-aged women in India.

  • Open Access

    Nutritional Deficiency as a Risk Factor for Cerebral Venous Thrombosis in Parts of Southern India: A Case‐Control Study

    by Agam Jain, S. Mythirayee, P. R. Srijithesh, Rita Christopher, Vijay Kumawat, Mailankody Pooja, Ravi Yadav, Girish Baburao Kulkarni, Pritam Raja, D. V. Sheshagiri, et al.

    The incidence of cerebral venous thrombosis (CVT) is anecdotally considered to be higher in parts of South India as compared with the West. The higher prevalence of CVT in this population is not accounted for by genetic thrombophilias, implicating acquired risk factors. As hyperhomocysteinemia and vitamin B12 deficiency are common in this population, we expected unique risk factors related to the diet. This case‐control study was done to examine the acquired risk factors and dietary patterns in these patients. Patients with CVT admitted from June 2021 to January 2023 were included in the study. Healthy attendants of other patients attending the emergency department for other neurological illnesses were recruited as controls. Clinical and biochemical data of patients were collected. Diet was assessed using a food frequency questionnaire. The contribution of food items to various nutrients (calories, protein, methionine, vitamin B12, folate, pyridoxine, and riboflavin) was calculated and compared with the recommended dietary allowance (RDA) and controls. The study enrolled 104 patients and 109 controls. The mean age of patients was 34.9 years (SD = 13.4). Hyperhomocysteinemia, anemia, alcohol consumption, folate deficiency, and vitamin B12 deficiency were observed in 63.5%, 46.2%, 45.2%, 37.5%, and 26%, respectively. Patients with a history of alcohol consumption had significantly higher homocysteine and lower folate. The diet of the patients had significantly higher odds of being protein‐deficient and folate‐deficient as compared with controls on multiple linear regression analysis. Poor nutrition, in the form of hyperhomocysteinemia and anemia, was the most common risk factor in the study population. Crucially, these risk factors are modifiable. Further large‐scale studies are needed to determine the incidence of CVT in this area and to evaluate the role of dietary interventions for risk modification.

  • Association of platelet ADP receptor variant rs1371097 with inadequate platelet response to aspirin in Indian patients

    by Pandarisamy Sundaravadivel, Rita Christopher, Sadanandavalli Retnaswami Chandra, Subasree Ramakrishnan

    On-aspirin platelet reactivity, wherein patients show sub-optimal or no response to antiplatelet therapy, occurs in 5-60% of subjects. The genetic etiology of such reactivity in patients with vascular diseases, especially ischemic stroke in the Indian population, is unknown. This study aimed to examine the genetic variations in the pathways of platelet aggregation and aspirin metabolism that could predict aspirin response. This is a prospective cohort study, which included 293 ischemic stroke patients on 150 mg aspirin for over 7 days. Platelet aggregation was assessed using light transmission aggregometry with 10 µM ADP and 0.5 mM arachidonic acid as agonist. After excluding patients with serum salicylic acid levels < 30 µg/mL, 230 individuals were analyzed. Candidate gene variants in COX1, COX2, GpIIb/IIIa, P2RY1, PEAR1, ITGB3, and UGT1A6, were genotyped using PCR-RFLP or allelic discrimination assays. The T allele of P2RY1 (rs1371097 C > T) was significantly associated with inadequate platelet response with an odds ratio of 1.71 (95% CI: 1.122-2.61; p = 0.0131). Carriers of this allele had a 3.46-fold increased risk of inadequate response after adjustment for age and gender. The P2RY1 (rs1371097 C > T) variant may be a potential genetic marker for inadequate response to aspirin in Indian ischemic stroke patients.


  • Targeted metabolomics in children with autism spectrum disorder with and without developmental regression

    by Chakkera Priyanka, Rita Christopher, Madhu Nagappa, John Vijay Sagar Kommu, Meghana Byalalu Krishnadevaraje, Durai Murukan Gunasekaran, Binu V. S. Nair, Raghavendra Kenchaiah, Nandakumar Dalavalaikodihalli Nanjaiah, Mariamma Philip, et al.

    Early diagnosis and intervention in children with autism spectrum disorder (ASD) is crucial. At present, diagnosis of ASD is primarily based on subjective tools. Identifying metabolic biomarkers will aid in early diagnosis of ASD complementing the assessment tools. The study aimed to conduct targeted metabolomic analysis and determine the plasma metabolites that can discriminate children with ASD from typically developing children (TD), and to determine the utility of machine learning in classifying ASD children based on the metabotypes. This was a multi-centric, analytical, case-control study conducted between April 2021–April 2023. Fasting plasma samples were obtained from seventy ASD and fifty-eight TD children, aged 2 to 12 years. Samples were quantitively analysed for 52 targeted metabolites (13 amino acids, 37 acylcarnitines, adenosine and 2-deoxyadenosine levels) using tandem mass spectrometry. An in-depth statistical analysis was performed. A total of 26 metabolites (11 amino acids, 14 acyl carnitines and adenosine) were found to be significantly (p < 0.005) different between ASD and TD children. Adenosine and amino acid levels were significantly decreased in ASD children. Among acyl carnitines, short- and long-chain acyl carnitine levels were significantly decreased, while medium-chain acyl carnitine levels were significantly increased in ASD children. Octenoylcarnitine-C8:1 (Cut-off value- 0.025 mmol/L, AUC- 0.683) and adenosine (Cut-off value- 0.025 mmol/L, AUC- 0.673) were found to predict children with ASD at a sensitivity of 55.7% and 57.1%, specificity of 79.3% and 72.4% respectively. Based on the metabolites, machine learning models like Support Vector Machine (SVM) and Random Forest (RF) were able to discriminate ASD from TD children with the classification accuracy score being highest in RF (79.487%, AUC- 0.800). Significant abnormalities in plasma metabolites were observed leading to disturbances in the Krebs cycle, urea cycle and fatty acid oxidation, suggesting mitochondrial dysfunction that may possibly contribute in the pathobiology of ASD. Octenoylcarnitine-C8:1 and Adenosine may serve as potential metabolic biomarkers for ASD.


  • The correlation between the severity of paroxysmal sympathetic hyperactivity and plasma catecholamine levels in patients with severe traumatic brain injury

    by Sonia Bansal, Dhritiman Chakrabarti, Mathangi Krishnakumar, Sundaravadivel P, Dhaval Shukla, Gorantla Padmasri, Rita Christopher, T N Sathyaprabha

    BackgroundThere is limited literature investigating the catecholamine levels in patients with paroxysmal sympathetic hyperactivity (PSH) after traumatic brain injury (TBI). The primary objective of this study was to correlate the severity of PSH (assessed using the PSH-Assessment measure [AM]) with plasma catecholamine levels at a resting state.MethodsIn this prospective case-control study, blood samples for epinephrine and norepinephrine estimation were obtained at rest on three consecutive days, only for 'cases' of PSH after severe TBI (s-TBI) and for control patients (matched for age, gender, and Glasgow coma scale [GCS].ResultsTwenty-seven patients with PSH and 16 controls were recruited. The median PSH-AM score was 20 and 9 in cases and controls, respectively. The epinephrine and norepinephrine levels at rest did not correlate with the severity of PSH assessed during PSH paroxysms (p = 0.949 and 0.975). Norepinephrine levels increased in PSH patients over the 3 consecutive days, once PSH was diagnosed (p = 0.022). The length of hospital stay was longer and the motor-GCS score was lower in PSH patients, with no differences in other outcomes between the groups.ConclusionCatecholamine levels in the inter-paroxysmal interval cannot be correlated with PSH severity assessed during the paroxysms. However, the results of the study need to be confirmed by a larger sample size as the study is underpowered.


  • Open Access

    Role of substance P in cerebral edema and association with an estimated specific gravity of the brain and an outcome prediction in post-traumatic cerebral edema

    by Subhas Konar, Dhaval Shukla, B. Indira Devi, Rita Christopher, Nishanth S, Louis Puybasset, Dhritiman Chakrabarti, P. Sundaravadivel, Shubham Nirmal


  • Clinicobiochemical Profile and Outcome of Children with Small Molecule Neurometabolic Disorders: A Tertiary Care Hospital Experience from India

    by Bidisha Banerjee, Supriya Shinde, Rita Christopher, Ullas Acharya

    Inborn Errors of Metabolism (IEM), though heterogenous, are not uncommon. Neurologic manifestations predominate. Without universal newborn screening, early diagnosis and treatment may lessen neuromorbidity. Hence, this study was done to understand small molecule neurometabolic disorders' presentation, diagnostic clues, and outcome. Small molecule neurometabolic disorder was diagnosed in 45 children (postneonatal onset) over 14 years (2008–2022) in a tertiary care hospital. Clinical and laboratory data were retrospectively analyzed. There were 26 boys and 19 girls. The median age at diagnosis was 19 months (interquartile range [IQR]: 8–38 months). The median diagnostic delay was 12 months in chronic encephalopathy (IQR: 1–24 months) and 1 month (IQR: 0.2–5.5 months) in the acute encephalopathy group (p ≤ 0.01). The presentation mode was chronic encephalopathy/myopathy in 29 (64.4%) and acute encephalopathy in 11 (24.4%). Diagnostic clues included unexplained developmental delay (n = 27, 60%), tone abnormalities (n = 26, 57.7%), movement disorder and ataxia (n = 16, 35.5%), acute encephalopathy (n = 11, 24.4%), neuroregression (n = 10, 22.2%), macrocephaly (n = 10, 22.2%), and alopecia (n = 4, 8.9%). Diagnostic/suggestive blood-spot tandem mass spectrometry (TMS) was seen in 34/38 (89.5%) children. Neuroimaging helped clinch the diagnosis in 17 (47%) children. Diagnostic categories were organic acidemias (n = 25, 55.6%), urea cycle disorders (n = 11, 24.4%), aminoacidopathies (n = 5, 11.1%), and fatty acid oxidation disorders (n = 4, 8.9%). The neurodevelopmental outcome was normal in 13 (28.8%), mild delay in 12 (26.6%), severe delay in 11 (24.4%), 3 deaths (6.6%), and 6 (13.3%) children being lost to follow-up. Overall, the outcome was favorable in 55% of cases. Unexplained developmental delay with tone abnormalities with or without movement disorders is a joint presentation of late-onset neurometabolic diseases. Neuroimaging studies and laboratory tests like blood-spot TMS help identify many small molecule disorders.